Antibiotic therapy in necrotising external otitis: case series of 32 patients and review of the literature.
Necrotising external otitis (NEO) is a rare but severe bone infection, usually due to Pseudomonas aeruginosa, the management of which is not standardised. Systemic antibiotic therapy is usually prescribed for at least 6 weeks, but no review has been published on this topic. We report our experience and have reviewed the literature regarding antibiotic therapy in NEO. Here we describe a case-series of consecutive NEO cases seen over an 8-year period (2004-2011) in a French tertiary-care teaching hospital. Since 2009 we have shortened the duration of antibiotic therapy to 6 weeks. We also present a review of the literature regarding antibiotic therapy in NEO. We include 32 NEO cases, with positive microbiological cultures in 30 cases. Among the 30 patients with suspected or proven P. aeruginosa infections, 27 received an initial combination therapy of ceftazidime and ciprofloxacin. The duration of antibiotic therapy and length of hospital stay were significantly reduced after 2009 (9.4 ± 3.2 weeks versus 5.8 ± 0.7, P < .0.001; and 18.2 ± 8.7 days versus 11.6 ± 6.9, P = .0.03, respectively). Patient outcomes were favorable in all cases, with a 14-month median duration of follow-up. Our literature review (30 case series) shows that initial combination therapy is associated with better outcomes as compared with single therapy (97 % versus 83 %, P < .0.001). We suggest 3 weeks of initial combination therapy (ceftazidime + ciprofloxacin, high doses) followed by 3 weeks single therapy with ciprofloxacin in susceptible P. aeruginosa NEO. A close collaboration between ear, nose and throat and infectious diseases specialists is needed.
Centre Hospitalier Universitaire de Nice, Service d'Infectiologie, Hôpital l'Archet 1, 151 Route Saint Antoine de Ginestière, BP 3079, 06202, Nice Cedex 3, France. pulcini.c@chu-nice.fr
C
C
Pulcini
P
P
Mahdyoun
E
E
Cua
I
I
Gahide
L
L
Castillo
N
N
Guevara
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D002442:Ceftazidime / Q000008:administration & dosage; D002939:Ciprofloxacin / Q000008:administration & dosage; D004359:Drug Therapy, Combination / Q000379:methods; D005260:Female; D005602:France; D006784:Hospitals, Teaching; D006801:Humans; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D009336:Necrosis / Q000188:drug therapy* / Q000473:pathology; D010032:Otitis Externa / Q000188:drug therapy* / Q000473:pathology; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D002939:Ciprofloxacin; D002442:Ceftazidime